<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678117</url>
  </required_header>
  <id_info>
    <org_study_id>NCI,IRB 2010014053.3</org_study_id>
    <nct_id>NCT02678117</nct_id>
  </id_info>
  <brief_title>Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain</brief_title>
  <official_title>Analgesic Potentials of Preoperative Oral Pregabalin,Intravenous Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain.(Randomized,Double-Blind Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of giving preoperative adjuvant drug as pregabalin or&#xD;
      magnesium sulphate or a combination of both drugs to decrease postoperative morphine&#xD;
      consumption and pain intensity in the first 24 hours in postoperative period . quarter of&#xD;
      patients receive single dose oral pregabalin 300mg 1 hour preoperatively ,other quarter&#xD;
      receive single intravenous Magnesium sulphate 50mg per Kg over 200ml saline over 20 minutes&#xD;
      preoperatively , other quarter receive combination of both drugs , the last quarter receive&#xD;
      placebo drugs . All patients receive 0.1mg per Kg intravenous morphine sulphate&#xD;
      intraoperatively&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium (Mg) acts on N-methyl-D-aspartate (NMDA) receptor as a non-competitive antagonist&#xD;
      with antinociceptive effects.&#xD;
&#xD;
      Gabapentin is an alkylated analogue of gammaaminobutyric acid (GABA) developed primarily as&#xD;
      an anticonvulsant drug. It was described as an analgesic drug for the treatment of&#xD;
      neuropathic pain in the 1990s. Although it is named Gabapentin,it does not bind at the GABA A&#xD;
      or GABA B receptor. It binds with high affinity for the α2δ subunit of the presynaptic&#xD;
      voltage-gated calcium channels, which reduce calcium-dependent release of pro-nociceptive&#xD;
      neurotransmitters in the pain pathways. Pregabalin is a structural analogue of GABA was&#xD;
      introduced after Gabapentin. If we used these drugs in combination to opioids preoperatively&#xD;
      as preventive analgesia may decrease postoperative opioid consumption and pain intensity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>patients are given regular intravenous morphine through patient controlled analgesia (PCA) and morphine consumption calculated from the PCA device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity using Visual Analogue Scale</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of pain intensity every 4 hours in the first 24 hours in postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery Time</measure>
    <time_frame>Immediately after ending the surgery</time_frame>
    <description>Time taken for recovery of the patient to be fully awake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of Heart Rate every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of Blood Pressure every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of Oxygen saturation every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of Respiratory Rate every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Postoperative nausea and vomiting scale (none 0, mild 1, moderate 2 , sever 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects from the used drugs</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation score</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Using Ramsay Sedation score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Pregabalin &amp; placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium sulphate &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin &amp; Magnesium sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will receive placebo medications at the same time and route of administration of other groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin &amp; Placebo</intervention_name>
    <arm_group_label>Pregabalin &amp; placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate &amp; Placebo</intervention_name>
    <arm_group_label>Magnesium sulphate &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin &amp; Magnesium sulphate</intervention_name>
    <arm_group_label>Pregabalin &amp; Magnesium sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ASA status of1 or 2&#xD;
&#xD;
          2. Patients undergoing thoracotomy&#xD;
&#xD;
          3. Body mass index (BMI): Less than forty and more than twenty.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - 1. Known sensitivity or contraindication to drugs used in the study. 2. History of&#xD;
        psychological disorders and/or chronic pain. 3. Patients receiving medical therapies that&#xD;
        are considered to result in tolerance to opioids.&#xD;
&#xD;
        4. Significant liver or kidney diseases that will affects the pharmacokinetics of study&#xD;
        drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naglaa A Ahmed, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Sagit M, Yalcin S, Polat H, Korkmaz F, Cetinkaya S, Somdas MA. Efficacy of a single preoperative dose of pregabalin for postoperative pain after septoplasty. J Craniofac Surg. 2013 Mar;24(2):373-5. doi: 10.1097/SCS.0b013e31827fece5.</citation>
    <PMID>23524696</PMID>
  </reference>
  <reference>
    <citation>Kiran S, Gupta R, Verma D. Evaluation of a single-dose of intravenous magnesium sulphate for prevention of postoperative pain after inguinal surgery. Indian J Anaesth. 2011 Jan;55(1):31-5. doi: 10.4103/0019-5049.76605.</citation>
    <PMID>21431050</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Ahmed Salah Ahmed Abd Elgalil</investigator_full_name>
    <investigator_title>Demonstrator in anaesthesia department, National Cancer Institute, Egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be available within 6 months of study completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

